Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer

BET bromodomain BRD4 and RAC1 oncogenes are considered important therapeutic targets for cancer and play key roles in tumorigenesis, survival and metastasis. However, combined inhibition of BRD4-RAC1 signaling pathways in different molecular subtypes of breast cancer including luminal-A, HER-2 posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Amjad, Shafarin, Jasmin, Unnikannan, Hema, Al-Jabi, Nour, Jabal, Rola Abu, Bajbouj, Khuloud, Muhammad, Jibran Sualeh, Hamad, Mawieh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579449/
https://www.ncbi.nlm.nih.gov/pubmed/34803511
http://dx.doi.org/10.7150/ijbs.62236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579449/
https://www.ncbi.nlm.nih.gov/pubmed/34803511
http://dx.doi.org/10.7150/ijbs.62236

Ejemplares similares